Skip to content

Modeling the Application of Chimeric Antigen Receptor T Cell Therapy to Eliminate Alloantibodies in Mice.

2026 · Methods in molecular biology · Vol 3053, pp. 305-322 · 0 citations
Medicine

TL;DR

Method for producing murine CAR T cells, their functional assessment in vitro, as well as their application in an in vivo transplant model, and methods for studying CAR T function in vitro using a cytotoxicity assay and in vivo using an islet transplant model.

View source

Similar papers

Review Sep 2026

In vivo CAR T-cell therapy: determinants of response and durability.

In vivo chimeric antigen receptor (CAR) T-cell therapy generates engineered lymphocytes inside the patient, bypassing leukapheresis, ex vivo manufacturing and, in many programs, lymphodepletion. Studies in relapsed or refractory multiple myeloma report deep responses with measurable residual disease negativity after B-...

Mohamed Abouelenein · 0 citations
Oct 2026

Safety of Autologous Infusion of CER T Cells in Nonhuman Primates

Cellular immunotherapies have shown great promise in the treatment of various diseases. Chimeric engulfment receptor (CER)-engineered T cells were developed to utilize the extracellular T-cell immunoglobulin and mucin domain-containing 4 (TIM-4) domain and intracellular engulfment signaling domains to target and enhanc...

K. Eichholz, A. Okoye, B. Varco-Merth et al. · 0 citations
Review Open access Nov 2026

CAR-T cell therapy in hematology malignancies: breaking barriers, engineering the future

Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a transformative approach for the treatment of hematological malignancies by enabling the genetic modification of a patient’s own T cells to recognize and eliminate malignant cells in an MHC-independent manner. In this mini review, we provide an overview o...

C. A. Alvizo-Báez, Ana Karina Chávez-Escamilla, S. Saavedra-Alonso et al. · 0 citations
Review Open access Nov 2026

Research Progress on Challenges in In Vivo CAR-T Cell Therapy

The emergence of chimeric antigen receptor (CAR) T-cell therapy heralds a paradigm shift in cancer immunotherapy. Different from in-vitro CAR-T products, in-vivo CAR-T engineering accomplishes in-situ reprogramming of endogenous T cells, making possible long-lasting anti-tumor cytotoxic activity, which is cost-effectiv...

Jia-Li Liu · 0 citations
#gene editing Review Oct 2026

T Cell Receptor-Engineered T Cell Therapy in Solid Tumors: Where We Stand and What's to Come.

T cell receptor-engineered T (TCR-T) cell therapy has emerged as a promising adoptive cellular therapy for solid tumors by enabling recognition of intracellular antigens presented via human leukocyte antigen (HLA) molecules. Unlike chimeric antigen receptor T cell therapy, TCR-T cell therapy targets a broader antigen r...

C. Ferriol Martinez, S. D'Angelo · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.